French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.
You’d be forgiven for thinking the BYD Atto 3 Evo is just a light facelift of the original (which was launched back in 2023). But appearances can be deceiving; it’s been massively overhauled, and BYD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results